**Supplementary Material**

**Table S1**: Studies excluded following full text screening

|  |  |  |  |
| --- | --- | --- | --- |
| Author, year | Title | Reason | Detail |
| Su et al., 2020 | Inhalation of Tetrandrine-hydroxypropyl-β-cyclodextrin Inclusion Complexes for Pulmonary Fibrosis Treatment | Route of administration | Intratracheal administration |
| Z. Wang & Li, 2018a | Raloxifene/SBE-β-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement | Route of administration | Intragastrical administration |
| Ren et al., 2019 | Preparation, optimization of the inclusion complex of glaucocalyxin A with sulfobutylether-β-cyclodextrin and antitumor study | Route of administration | Intravenous administration |
| M. Chen et al., 2017 | Preparation, characterization and in vivo evaluation of a formulation of dantrolene sodium with hydroxypropyl—cyclodextrin | Route of administration | Intragastric administration |
| X. Chen et al., 2010 | Enhanced aqueous solubility and bioavailability of capsaicin by the preparation of an inclusion complex | Route of administration | Subcutaneous administration |
| Ren et al., 2020 | Inclusion Complex of Docetaxel with Sulfobutyl Ether β-Cyclodextrin: Preparation, In Vitro Cytotoxicity and In Vivo Safety | Route of administration | Tail injection |
| N. Li et al., 2018 | Preparation of curcumin-hydroxypropyl-β-cyclodextrin inclusion complex by cosolvency-lyophilization procedure to enhance oral bioavailability of the drug | Route of administration | Intravenous administration |
| Manne et al., 2021 | Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs | Species | Wistar rats were used for this study |
| D. Xu et al., 2021 | Preparation, characterization and pharmacokinetic studies of sulfobutyl ether-β-cyclodextrin-toltrazuril inclusion complex | Species | Broilers were used for this study |
| L. Zhang et al., 2020 | In Vitro and In Vivo Comparison of Curcumin-Encapsulated Chitosan-Coated Poly (lactic-co-glycolic acid) Nanoparticles and Curcumin/Hydroxypropyl-β-Cyclodextrin Inclusion Complexes Administered Intranasally as Therapeutic Strategies for Alzheimer’s Disease | Species | C57BL/6 mice were used for this study |
| Erdoğar et al., 2020 | Improved oral bioavailability of anticancer drug tamoxifen through complexation with water soluble cyclodextrins: in vitro and in vivo evaluation | Species | Balb-c mice were used for this study |
| Lodagekar et al., 2019 | Formulation and evaluation of cyclodextrin complexes for improved anticancer activity of repurposed drug: Niclosamide | Species | Balb-c mice were used for this study |
| W. Zhang et al., 2019 | MOF Capacitates Cyclodextrin to Mega-Load Mode for High-Efficient Delivery of Valsartan | Species | Beagle dogs were used for this study |
| Creteanu et al., 2019 | Study on the Role of the Inclusion Complexes with 2-Hydroxypropyl-*β*-cyclodextrin for Oral Administration of Amiodarone | Species | Wistar rats were used for this study |
| Al-Gethmy et al., 2019 | Optimization of the Factors Affecting the Absorption of Vardenafil from Oral Disintegrating Tablets: A Clinical Pharmacokinetic Investigation | Species | Human were used for this study |
| Fan et al., 2019 | Comparative muscle irritation and pharmacokinetics of florfenicol-hydroxypropyl-β-cyclodextrin inclusion complex freeze-dried powder injection and florfenicol commercial injection in beagle dogs | Species | Beagle dogs were used for this study |
| Purpura et al., 2018 | Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects | Species | Human were used for this study |
| L. Zhang et al., 2018 | The hydroxypropyl–β-cyclodextrin complexation of toltrazuril for enhancing bioavailability | Species | Rabbits were used for this study |
| D. Wang et al., 2017 | Preparation and Characterization of the Sulfobutylether-β-Cyclodextrin Inclusion Complex of Amiodarone Hydrochloride with Enhanced Oral Bioavailability in Fasted State | Species | Beagle Dogs were used for this study |
| Mady & Farghaly Aly, 2017 | Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins | Species | Albino rabbits were used for this study |
| Darekar et al., 2016 | Characterization and in vivo evaluation of lacidipine inclusion complexes with β-cyclodextrin and its derivatives | Species | Wistar rats were used for this study |
| Dahiya et al., 2015 | Improved Pharmacokinetics of Aceclofenac Immediate Release Tablets Incorporating its Inclusion Complex with Hydroxypropyl-β-Cyclodextrin | Species | Wistar rats were used for this study |
| Gidwani & Vyas, 2015 | Inclusion complexes of bendamustine with β -CD, HP- β -CD and Epi- β -CD: in-vitro and in-vivo evaluation | Species | Wistar rats were used for this study |
| Ren et al., 2014 | Preparation and Pharmacokinetic Study of Aprepitant–Sulfobutyl Ether-β-Cyclodextrin Complex | Species | Beagle dogs were used for this study |
| J. Wu et al., 2013 | Sulfobutylether-β-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel | Species | Wistar rats were used for this study |
| Ridhurkar et al., 2013 | Inclusion complex of aprepitant with cyclodextrin: Evaluation of physico-chemical and pharmacokinetic properties | Species | Human were used for this study |
| C. Wu et al., 2013 | Comparative pharmacokinetics and bioavailability of four alkaloids in different formulations from Corydalis Decumbens | Species | Wistar rats were used for this study |
| Chauhan et al., 2013 | Inclusion complex of colchicine in hydroxypropyl-β-cyclodextrin tenders better solubility and improved pharmacokinetics | Species | Mice were used for this study |
| Zeng et al., 2013 | In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations | Species | Beagle dogs were used for this study |
| Hwang et al., 2012 | Characterization, stability, and pharmacokinetics of sibutramine/b-cyclodextrin inclusion complex | Species | Human were used for this study |
| Huang et al., 2011 | Pharmacokinetics, Efficacy, and Safety Evaluation of Docetaxel/Hydroxypropyl-Sulfobutyl-β-Cyclodextrin Inclusion Complex | Species | Albino rabbits were used for this study |
| Ansari et al., 2011 | Improving the solubility and bioavailability of dihydroartemisinin by solid dispersions and inclusion complexes | Species | Swiss mice were used for this study |
| Ribeiro et al., 2010 | Prolonged Absorption of Antimony(V) by the Oral Route from Non-inclusion Meglumine Antimoniate– β -cyclodextrin Conjugates | Species | Beagle dogs were used for this study |
| Žmitek et al., 2008 | Relative bioavailability of two forms of a novel water-soluble coenzyme Q10 | Species | Human were used for this study |
| Yan et al., 2008 | Characterization and In Vivo Evaluation of an Inclusion Complex of Oridonin and 2-hydroxypropyl- β -cyclodextrin | Species | Wistar rats were used for this study |
| Tayade & Vavia, 2006 | [Inclusion complexes of Ketoprofen with beta-cyclodextrins: Oral pharmacokinetics of Ketoprofen in human](https://www.ijpsonline.com/articles/inclusion-complexes-of-ketoprofen-with-betacyclodextrins-oral-pharmacokinetics-of-ketoprofen-in-human.html) | Species | Human were used for this study |
| Ghorab et al., 2004 | Tablet formulation containing meloxicam and β-cyclodextrin: Mechanical characterization and bioavailability evaluation | Species | Human were used for this study |
| Géczy et al., 2000 | The inclusion of fluoxetine into γ-cyclodextrin increases its bioavailability: behavioural, electrophysiological and pharmacokinetic studies | Species | Human were used for this study |
| J. Li et al., 2021 | Rational formulation engineering of fraxinellone utilizing 6-O-α-D-maltosyl-β-cyclodextrin for enhanced oral bioavailability and hepatic fibrosis therapy | Species | Wistar rats were used for this study |
| Y. Xu et al., 2019 | Chloramphenicol/sulfobutyl ether-β-cyclodextrin complexes in an ophthalmic delivery system: prolonged residence time and enhanced bioavailability in the conjunctival sac | Species | Rabbits were used for this study |
| Ding et al., 2019 | Pharmacokinetics and liver uptake of three Schisandra lignans in rats after oral administration of liposome encapsulating β-cyclodextrin inclusion compound of Schisandra extract | Species | Wistar rats were used for this study |
| H.-B. Wang et al., 2017 | A pH-independent instantaneous release of flurbiprofen: a study of the preparation of complexes, their characterization and in vitro/in vivo evaluation | Species | Wistar rats were used for this study |
| Leonardi et al., 2013 | Effects of benznidazole:cyclodextrin complexes on the drug bioavailability upon oral administration to rats | Species | Wistar rats were used for this study |
| Zeng et al., 2013 | Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes | Species | Rabbits were used for this study |
| Frézard et al., 2008 | Enhanced oral delivery of antimony from meglumine antimoniate/β-cyclodextrin nanoassemblies | Species | Beagle dogs were used for this study |
| Patel & Rajput, 2009 | Enhancement of Oral Bioavailability of Cilostazol by Forming its Inclusion Complexes | Species | New Zealand rabbits were used for this study |
| Nie et al., 2007 | In Vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-β-cyclodextrin | Species | Rabbits were used for this study |
| Hassan et al., 2007 | Enhancement of dissolution amount and *in vivo* bioavailability of itraconazole by complexation with β-cyclodextrin using supercritical carbon dioxide | Species | Wistar rats were used for this study |
| Piette et al., 2006 | Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions | Species | Sheep were used for this study |
| Evrard et al., 2002 | Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-β-cyclodextrin | Species | Sheep were used for this study |
| Miyake et al., 2000 | Improvement of Solubility and Oral Bioavailability of Rutin by Complexation with 2-Hydroxypropyl-b-cyclodextrin | Species | Beagle dogs were used for this study |
| Veiga et al., 2000 | Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes | Species | Rabbits were used for this study |

**References**

Al-Gethmy, H. A., Fahmy, U. A., Alhakamy, N. A., Ahmed, O. A. A., & El-Say, K. M. (2019). Optimization of the factors affecting the absorption of vardenafil from oral disintegrating tablets: A clinical pharmacokinetic investigation. *Pharmaceutics*, *11*(1), 11.

Ansari, M. T., Batty, K. T., Iqbal, I., & Sunderland, V. B. (2011). Improving the solubility and bioavailability of dihydroartemisinin by solid dispersions and inclusion complexes. *Archives of Pharmacal Research*, *34*, 757–765.

Chauhan, R., Madan, J., Kaushik, D., Sardana, S., Pandey, R. S., & Sharma, R. (2013). Inclusion complex of colchicine in hydroxypropyl-β-cyclodextrin tenders better solubility and improved pharmacokinetics. *Pharmaceutical Development and Technology*, *18*(2), 313–322.

Chen, M., Wu, Q., Jiang, J., Jin, X., Liu, S., Wang, M., & Zhao, C. (2017). Preparation, characterization and in vivo evaluation of a formulation of dantrolene sodium with hydroxypropyl-β-cyclodextrin. *Journal of Pharmaceutical and Biomedical Analysis*, *135*, 153–159.

Chen, X., Sun, X., Ren, K., Zhang, X., Zhang, Z., & Gong, T. (2010). Enhanced aqueous solubility and bioavailability of capsaicin by the preparation of an inclusion complex. *Arzneimittelforschung*, *60*(09), 571–574.

Creteanu, A., Pamfil, D., Vasile, C., Tantaru, G., Ghiciuc, C. M., Ochiuz, L., Ghilan, A., & Macsim, A. M. (2019). Study on the Role of the Inclusion Complexes with 2-Hydroxypropyl-β-cyclodextrin for Oral Administration of Amiodarone. *International Journal of Polymer Science*, *2019*(1), 1695189.

Dahiya, S., Kaushik, A., & Pathak, K. (2015). Improved pharmacokinetics of aceclofenac immediate release tablets incorporating its inclusion complex with hydroxypropyl-β-cyclodextrin. *Scientia Pharmaceutica*, *83*(3), 501–510.

Darekar, T., Aithal, K. S., Shirodkar, R., Kumar, L., Attari, Z., & Lewis, S. (2016). Characterization and in vivo evaluation of lacidipine inclusion complexes with β-cyclodextrin and its derivatives. *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, *84*, 225–235.

Ding, Z., Xiao, J., Zhang, Y., Jiang, Y., Chen, W., Hu, J., Guo, Y., & Zhang, B. (2019). Pharmacokinetics and liver uptake of three Schisandra lignans in rats after oral administration of liposome encapsulating β-cyclodextrin inclusion compound of Schisandra extract. *Journal of Liposome Research*, *29*(2), 121–132.

Erdoğar, N., Nemutlu, E., \.Iskit, A. B., Kara, S. C., Teksin, Z. Ş., & Bilensoy, E. (2020). Improved oral bioavailability of anticancer drug tamoxifen through complexation with water soluble cyclodextrins: in vitro and in vivo evaluation. *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, *96*, 81–91.

Evrard, B., Chiap, P., DeTullio, P., Ghalmi, F., Piel, G., Van Hees, T., Crommen, J., Losson, B., & Delattre, L. (2002). Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-β-cyclodextrin. *Journal of Controlled Release*, *85*(1–3), 45–50.

Fan, G., Zhang, L., Shen, Y., Shu, G., Yuan, Z., Lin, J., Zhang, W., Peng, G., Zhong, Z., Yin, L., & others. (2019). Comparative muscle irritation and pharmacokinetics of florfenicol-hydroxypropyl-β-cyclodextrin inclusion complex freeze-dried powder injection and florfenicol commercial injection in beagle dogs. *Scientific Reports*, *9*(1), 16739.

Frézard, F., Martins, P. S., Bahia, A. P. C. O., Le Moyec, L., de Melo, A. L., Pimenta, A. M. C., Salerno, M., da Silva, J. B. B., & Demicheli, C. (2008). Enhanced oral delivery of antimony from meglumine antimoniate/β-cyclodextrin nanoassemblies. *International Journal of Pharmaceutics*, *347*(1–2), 102–108.

Géczy, J., Bruhwyler, J., Scuvée-Moreau, J., Seutin, V., Masset, H., Van Heugen, J. C., Dresse, A., Lejeune, C., Decamp, E., Szente, L., & others. (2000). The inclusion of fluoxetine into γ-cyclodextrin increases its bioavailability: behavioural, electrophysiological and pharmacokinetic studies. *Psychopharmacology*, *151*, 328–334.

Ghorab, M. M., Abdel-Salam, H. M., El-Sayad, M. A., & Mekhel, M. M. (2004). Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. *Aaps Pharmscitech*, *5*, 63–68.

Gidwani, B., & Vyas, A. (2015). Inclusion complexes of bendamustine with β-CD, HP-β-CD and Epi-β-CD: in-vitro and in-vivo evaluation. *Drug Development and Industrial Pharmacy*, *41*(12), 1978–1988.

Hassan, H. A., Al-Marzouqi, A. H., Jobe, B., Hamza, A. A., & Ramadan, G. A. (2007). Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with β-cyclodextrin using supercritical carbon dioxide. *Journal of Pharmaceutical and Biomedical Analysis*, *45*(2), 243–250.

Huang, X.-X., Zhou, C.-L., Wang, H., Chen, C., Yu, S.-Q., Xu, Q., Zhu, Y.-Y., & Ren, Y. (2011). Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex. *AAPS Pharmscitech*, *12*, 665–672.

Hu, Q., Fu, X., Su, Y., Wang, Y., Gao, S., Wang, X., Xu, Y., & Yu, C. (2021). Enhanced oral bioavailability of koumine by complexation with hydroxypropyl-β-cyclodextrin: preparation, optimization, ex vivo and in vivo characterization. *Drug Delivery*, *28*(1), 2415–2426. https://doi.org/10.1080/10717544.2021.1998248

Hwang, Y. Y., Shin, D. C., Nam, Y. S., & Cho, B.-K. (2012). Characterization, stability, and pharmacokinetics of sibutramine/β-cyclodextrin inclusion complex. *Journal of Industrial and Engineering Chemistry*, *18*(4), 1412–1417.

Igami, K., Ozawa, M., Inoue, S., Iohara, D., Miyazaki, T., Shinoda, M., Anraku, M., Hirayama, F., & Uekama, K. (2016). The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics. *Journal of Pharmacy and Pharmacology*, *68*(5), 646–654. https://doi.org/10.1111/jphp.12468

Kong, R., Zhu, X., Meteleva, E. S., Dushkin, A. V, & Su, W. (2018). Physicochemical characteristics of the complexes of simvastatin and atorvastatin calcium with hydroxypropyl-β-cyclodextrin produced by mechanochemical activation. *Journal of Drug Delivery Science and Technology*, *46*, 436–445. https://doi.org/https://doi.org/10.1016/j.jddst.2018.05.018

Lee, P. S., Han, J.-Y., Song, T. W., Sung, J. H., Kwon, O.-S., Song, S., & Chung, Y. B. (2006). Physicochemical characteristics and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexed with β-cyclodextrin. *International Journal of Pharmaceutics*, *316*(1–2), 29–36.

Leonardi, D., Bombardiere, M. E., & Salomon, C. J. (2013). Effects of benznidazole: cyclodextrin complexes on the drug bioavailability upon oral administration to rats. *International Journal of Biological Macromolecules*, *62*, 543–548.

Li, J., Feng, T., Yang, W., Xu, Y., Wang, S., Cai, H., Liu, Z., Qiang, H., & Zhang, J. (2021). Rational formulation engineering of fraxinellone utilizing 6-O-α-D-maltosyl-β-cyclodextrin for enhanced oral bioavailability and hepatic fibrosis therapy. *Drug Delivery*, *28*(1), 1890–1902.

Li, N., Wang, N., Wu, T., Qiu, C., Wang, X., Jiang, S., Zhang, Z., Liu, T., Wei, C., & Wang, T. (2018). Preparation of curcumin-hydroxypropyl-β-cyclodextrin inclusion complex by cosolvency-lyophilization procedure to enhance oral bioavailability of the drug. *Drug Development and Industrial Pharmacy*, *44*(12), 1966–1974.

Li, R., Bao, R., Yang, Q.-X., Wang, Q.-L., Adu-Frimpong, M., Wei, Q.-Y., Elmurat, T., Ji, H., Yu, J.-N., & Xu, X.-M. (2019). [6]-Shogaol/β-CDs inclusion complex: preparation, characterisation, in vivo pharmacokinetics, and in situ intestinal perfusion study. *Journal of Microencapsulation*, *36*(5), 500–512. https://doi.org/10.1080/02652048.2019.1649480

Liu, H., Yang, G., Tang, Y., Cao, D., Qi, T., Qi, Y., & Fan, G. (2013). Physicochemical characterization and pharmacokinetics evaluation of β-caryophyllene/β-cyclodextrin inclusion complex. *International Journal of Pharmaceutics*, *450*(1–2), 304–310.

Lodagekar, A., Borkar, R. M., Thatikonda, S., Chavan, R. B., Naidu, V. G. M., Shastri, N. R., Srinivas, R., & Chella, N. (2019). Formulation and evaluation of cyclodextrin complexes for improved anticancer activity of repurposed drug: Niclosamide. *Carbohydrate Polymers*, *212*, 252–259.

Mady, F. M., & Farghaly Aly, U. (2017). Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins. *Drug Design, Development and Therapy*, 1681–1692.

Manne, A. S. N., Hegde, A. R., Raut, S. Y., Rao, R. R., Kulkarni, V. I., & Mutalik, S. (2021). Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. *Drug Delivery and Translational Research*, *11*, 1273–1287.

Miyake, K., Arima, H., Hirayama, F., Yamamoto, M., Horikawa, T., Sumiyoshi, H., Noda, S., & Uekama, K. (2000). Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-β-cyclodextrin. *Pharmaceutical Development and Technology*, *5*(3), 399–407.

Nie, S., Fan, X., Peng, Y., Yang, X., Wang, C., & Pan, W. (2007). In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-β-cyclodextrin. *Archives of Pharmacal Research*, *30*, 991–1001.

Patel, S. G., & Rajput, S. J. (2009). Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. *AAPS PharmSciTech*, *10*, 660–669.

Piette, M., Evrard, B., Frankenne, F., Chiap, P., Bertholet, P., Castagne, D., Foidart, J.-M., Delattre, L., & Piel, G. (2006). Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions. *European Journal of Pharmaceutical Sciences*, *28*(3), 189–195.

Purpura, M., Lowery, R. P., Wilson, J. M., Mannan, H., Münch, G., & Razmovski-Naumovski, V. (2018). Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. *European Journal of Nutrition*, *57*, 929–938.

Ren, L., Wang, J., & Chen, G. (2019). Preparation, optimization of the inclusion complex of glaucocalyxin A with sulfobutylether-β-cyclodextrin and antitumor study. *Drug Delivery*, *26*(1), 309–317.

Ren, L., Yang, X., Guo, W., Wang, J., & Chen, G. (2020). Inclusion complex of docetaxel with sulfobutyl ether β-cyclodextrin: preparation, in vitro cytotoxicity and in vivo safety. *Polymers*, *12*(10), 2336.

Ren, L., Zhou, Y., Wei, P., Li, M., & Chen, G. (2014). Preparation and pharmacokinetic study of aprepitant–sulfobutyl ether-β-cyclodextrin complex. *Aaps Pharmscitech*, *15*, 121–130.

Ribeiro, R. R., Ferreira, W. A., Martins, P. S., Neto, R. L. M., Rocha, O. G. F., Le Moyec, L., Demicheli, C., & Frézard, F. (2010). Prolonged absorption of antimony (V) by the oral route from non-inclusion meglumine antimoniate–β-cyclodextrin conjugates. *Biopharmaceutics & Drug Disposition*, *31*(2–3), 109–119.

Ridhurkar, D. N., Ansari, K. A., Kumar, D., Kaul, N. S., Krishnamurthy, T., Dhawan, S., & Pillai, R. (2013). Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. *Drug Development and Industrial Pharmacy*, *39*(11), 1783–1792.

Su, W., Liang, Y., Meng, Z., Chen, X., Lu, M., Han, X., Deng, X., Zhang, Q., Zhu, H., & Fu, T. (2020). Inhalation of tetrandrine-hydroxypropyl-β-cyclodextrin inclusion complexes for pulmonary fibrosis treatment. *Molecular Pharmaceutics*, *17*(5), 1596–1607.

Tayade, P., & Vavia, P. (2006). Inclusion complexes of Ketoprofen with?-cyclodextrins: Oral pharmacokinetics of Ketoprofen in human. *Indian Journal of Pharmaceutical Sciences*, *68*(2).

Tian, R., Wang, H., Xiao, Y., Hu, P., Du, R., Shi, X., Wang, Z., & Xie, Y. (2020). Fabrication of Nanosuspensions to Improve the Oral Bioavailability of Total Flavones from Hippophae rhamnoides L. and their Comparison with an Inclusion Complex. *AAPS PharmSciTech*, *21*(7), 249. https://doi.org/10.1208/s12249-020-01788-9

Veiga, F., Fernandes, C., & Teixeira, F. (2000). Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. *International Journal of Pharmaceutics*, *202*(1–2), 165–171.

Wang, D., Chen, G., & Ren, L. (2017). Preparation and characterization of the sulfobutylether-β-cyclodextrin inclusion complex of amiodarone hydrochloride with enhanced oral bioavailability in fasted state. *Aaps Pharmscitech*, *18*, 1526–1535.

Wang, H.-B., Yang, F.-F., Gai, X.-M., Cheng, B.-C., Li, J.-Y., Pan, H., Yang, X.-G., & Pan, W.-S. (2017). A pH-independent instantaneous release of flurbiprofen: A study of the preparation of complexes, their characterization and in vitro/in vivo evaluation. *Drug Development and Industrial Pharmacy*, *43*(9), 1460–1471.

Wang, Z., & Li, Y. (2018a). Raloxifene/SBE-β-CD inclusion complexes formulated into nanoparticles with chitosan to overcome the absorption barrier for bioavailability enhancement. *Pharmaceutics*, *10*(3), 76.

Wang, Z., & Li, Y. (2018b). Raloxifene/SBE-β-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement. *Pharmaceutics*, *10*(3). https://doi.org/10.3390/pharmaceutics10030076

Wu, C., Yan, R., Zhang, R., Bai, F., Yang, Y., Wu, Z., & Wu, A. (2013). Comparative pharmacokinetics and bioavailability of four alkaloids in different formulations from Corydalis decumbens. *Journal of Ethnopharmacology*, *149*(1), 55–61.

Wu, J., Shen, Q., & Fang, L. (2013). Sulfobutylether-β-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel. *Drug Development and Industrial Pharmacy*, *39*(7), 1010–1019.

Xie, J., Yang, F., Shi, X., Zhu, X., Su, W., & Wang, P. (2013). Improvement in solubility and bioavailability of puerarin by mechanochemical preparation. *Drug Development and Industrial Pharmacy*, *39*(6), 826–835.

Xu, C., Tang, Y., Hu, W., Tian, R., Jia, Y., Deng, P., & Zhang, L. (2014). Investigation of inclusion complex of honokiol with sulfobutyl ether-β-cyclodextrin. *Carbohydrate Polymers*, *113*, 9–15.

Xu, D., Li, X., Huang, Y., Tang, Z., Ran, C., Jing, B., Yin, L., Lin, J., Fu, H., Tang, H., & others. (2021). Preparation, characterization and pharmacokinetic studies of sulfobutyl ether-β-cyclodextrin-toltrazuril inclusion complex. *Journal of Molecular Structure*, *1223*, 128969.

Xu, Y., Zhang, C., Zhu, X., Wang, X., Wang, H., Hu, G., Fu, Q., & He, Z. (2019). Chloramphenicol/sulfobutyl ether-β-cyclodextrin complexes in an ophthalmic delivery system: prolonged residence time and enhanced bioavailability in the conjunctival sac. *Expert Opinion on Drug Delivery*, *16*(6), 657–666.

Yan, Z., Xu, W., Sun, J., Liu, X., Zhao, Y., Sun, Y., Zhang, T., & He, Z. (2008). Characterization and in vivo evaluation of an inclusion complex of oridonin and 2-hydroxypropyl-β-cyclodextrin. *Drug Development and Industrial Pharmacy*, *34*(6), 632–641.

Zeng, F., Wang, L., Zhang, W., Shi, K., & Zong, L. (2013). Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes. *AAPS PharmSciTech*, *14*, 854–860.

Zhang, L., Liu, M., Lu, C., Ren, D., Fan, G., Liu, C., Liu, M., Shu, G., Peng, G., Yuan, Z., & others. (2018). The hydroxypropyl–β-cyclodextrin complexation of toltrazuril for enhancing bioavailability. *Drug Design, Development and Therapy*, 583–589.

Zhang, L., Yang, S., Wong, L. R., Xie, H., & Ho, P. C.-L. (2020). In vitro and in vivo comparison of curcumin-encapsulated chitosan-coated poly (lactic-co-glycolic acid) nanoparticles and curcumin/hydroxypropyl-β-Cyclodextrin inclusion complexes administered intranasally as therapeutic strategies for Alzheimer’s Disease. *Molecular Pharmaceutics*, *17*(11), 4256–4269.

Zhang, W., Guo, T., Wang, C., He, Y., Zhang, X., Li, G., Chen, Y., Li, J., Lin, Y., Xu, X., & others. (2019). MOF capacitates cyclodextrin to mega-load mode for high-efficient delivery of valsartan. *Pharmaceutical Research*, *36*(8), 117.

Žmitek, J., Šmidovnik, A., Fir, M., Prošek, M., Žmitek, K., Walczak, J., & Pravst, I. (2008). Relative bioavailability of two forms of a novel water-soluble coenzyme Q10. *Annals of Nutrition and Metabolism*, *52*(4), 281–287.

Zuo, Z., Tam, Y. K., Diakur, J., & Wiebe, L. I. (2002). Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. *J Pharm Pharm Sci*, *5*(3), 292–298.